Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 0.8× sales vs its 13.3× historical median P/S.
Fair value ≈ $9.15 · price $0.55 today
Undervalued · 94% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
@CapitalismUSA @Theverypatientone In terms of EV for LNP $ABUS will get about 35%-40% and $ROIV 65%-60%. $140B * .12*.35 = $6B at the very minimum and as high as mid to high teens if $MRNS, $BNTX, $PFE dare to gamble and go to trail.
#SPMNOTES
EXAMPLES OF G-101 SPM AI's STOCK PICKS
As of January 2026, the G-101 SPM AI algorithm, co-authored by Christopher Netelkos at Northridge Company, has documented a certified history of 3,097 stock picks since its inception in March 2023.
The following are documented examples of stocks selected by the algorithm and their subsequent performance:
Documented Winners (Historical to 2026)
According to performance audits and strategy reports published in January 2026, the AI identified several major individual winners before significant rallies:
Thyssenkrupp (ETR: TKAG): Gained +223% after being selected by the AI.
Super Micro Computer (NASDAQ: $SMCI): Achieved a +185.8% return while active in the AI's strategy.
ABL Bio Inc (KQ: 298380): Increased by +170.30% following its selection.
ViaSat Inc (NASDAQ: $VSAT): Saw a +163% rise after being picked.
Colab Cloud Platforms (BO: COLA): Gained +111.80%.
Banco Santander (NYSE: SAN): Achieved a +104.45% return.
Nvidia (NASDAQ: $NVDA): Recorded a +226.7% gain while held within the AI strategy.
Specific Case Study: Marinus Pharmaceuticals ($MRNS)
A notable 2024–2025 case study from Christopher Netelkos’s "SPM Notes" highlights the algorithm's timing:
The AI issued a bid at $1.50.
The position was exited on January 29, 2024, at $10.26 after the "SPM tag" dropped, representing a substantial gain before the subsequent stock decline.
Current Strategy Performance (January 2026)
As of early January 2026, the AI's "Top Value" strategy has reportedly delivered an 83.20% return, outperforming its benchmark by 33.85%. The algorithm continues to process information from 145 unstructured data sources to identify "smart" data trends that prioritize non-human intervention over traditional conventional analytics.
GLMD meets a lot of criteria 🔥 Biotech history shows what’s possible when the right setup meets the right spark…
📈 $RCUS — $2 to $25+ on oncology momentum
📈 $CRBP — $0.90 to $9+ on FDA buzz
📈 $XBIO — under $1 to $6+ on low-float madness
📈 $MRNS — $1.50 to $13+ on epilepsy pipeline news
⬇️⬇️⬇️⬇️
Now look at $GLMD
🔹 Trading under $2
🔹 Book value near $12
🔹 Strong cash position
🔹 Biotech catalyst potential
🔹 Tight float 👀
Not a guarantee. Not advice. Just perspective.
In biotech land, moves like these have happened before.
GLMD has the ingredients. Now it’s about the catalyst.
